The Role of Metformin and Colesevelam in Human GLP-1 Secretion
NCT ID: NCT02050074
Last Updated: 2014-10-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2014-01-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
NCT01656057
Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes
NCT02497313
Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota
NCT02061124
Effect of Bile Acids on GLP-1 Secretion
NCT01666223
Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome
NCT00856700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Colesevelam
Colesevelam
Metformin
Metformin
Placebo
Placebo
Colesevelam + exendin (9-39)
Colesevelam
Metformin + exendin (9-39)
Metformin
Placebo + + exendin (9-39)
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colesevelam
Metformin
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 23kg/m2
* HbA1c \<9 %
* Informed concent
Exclusion Criteria
* Chronic intestinal disease
* History of liver and / or gallbladder disease
* Nephropathy (se-creatinine \>110 µM and / or albuminuria)
* Insulin or GLP-1-based antidiabetic treatment
* History of cholecystectomy or surgical resection of bowel segment
* BMI \<23kg/m2 or BMI \>35 kg/m2
* Pregnancy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hansen
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diabetes Research Division, Department of Medicine, Gentofte Hospital
Hellerup, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP, Hansen JS, Rohde U, Liou AP, Jackson ML, de Fontgalland D, Rabbitt P, Hollington P, Sposato L, Due S, Wattchow DA, Rehfeld JF, Holst JJ, Keating DJ, Vilsboll T, Knop FK. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight. 2018 Dec 6;3(23):e93936. doi: 10.1172/jci.insight.93936.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-1-2013-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.